CN117024517B - Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof - Google Patents
Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN117024517B CN117024517B CN202311038473.6A CN202311038473A CN117024517B CN 117024517 B CN117024517 B CN 117024517B CN 202311038473 A CN202311038473 A CN 202311038473A CN 117024517 B CN117024517 B CN 117024517B
- Authority
- CN
- China
- Prior art keywords
- short peptide
- polypeptide
- solution
- cell
- bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 59
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 56
- 102000002260 Alkaline Phosphatase Human genes 0.000 title claims abstract description 25
- 108020004774 Alkaline Phosphatase Proteins 0.000 title claims abstract description 25
- 239000004568 cement Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000004044 response Effects 0.000 title abstract description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 32
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims abstract description 23
- 101710176384 Peptide 1 Proteins 0.000 claims abstract description 23
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 75
- 239000011347 resin Substances 0.000 claims description 25
- 229920005989 resin Polymers 0.000 claims description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 9
- 239000012043 crude product Substances 0.000 claims description 9
- 238000001764 infiltration Methods 0.000 claims description 9
- 230000008595 infiltration Effects 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 238000006243 chemical reaction Methods 0.000 abstract description 16
- 210000002865 immune cell Anatomy 0.000 abstract description 15
- 239000002121 nanofiber Substances 0.000 abstract description 9
- 230000000903 blocking effect Effects 0.000 abstract description 8
- 230000014759 maintenance of location Effects 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 238000013459 approach Methods 0.000 abstract description 4
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 238000001553 co-assembly Methods 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000007115 recruitment Effects 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 abstract 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000002619 cancer immunotherapy Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000002074 nanoribbon Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- -1 Hexafluorophosphate Chemical compound 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides an alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide, a preparation method and application thereof, and relates to the technical field of medicine and pharmacy. The polypeptide is obtained by co-assembling short peptide 1 and short peptide 2, and the like. The invention provides an innovative method, which utilizes the design of an ALP-responsive dual-specificity supermolecule cell engagement device (Supra-BiCE) to realize the targeted combination between cancer cells and immune cells so as to enhance the immune treatment effect. Through the co-assembly of blocking peptides, the Supra-BiCE can simultaneously recognize TIGIT on the surface of immune cells and PD-L1 on the surface of tumor cells, and through the conversion from ALP-guided nanofibers to long nanofibers, the binding affinity is improved, the recruitment of tumor-specific immune cells is ensured, and the retention in tumors is prolonged. This approach provides new strategies and tools for enhancing the effectiveness of immunotherapy.
Description
Technical Field
The invention relates to the technical field of medicine and pharmacy, in particular to an alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide, a preparation method and application thereof.
Background
Cancer immunotherapy has completely altered the field of clinical oncology by using checkpoint blocking antibodies and chimeric antigen receptor T cell therapies. However, current approaches have certain limitations, including low response rates of checkpoint inhibitors and limited efficacy of cell therapies on solid tumors. One of the key factors responsible for the poor efficacy of cancer immunotherapy is insufficient infiltration and impaired function of immune cells within solid tumors. Strategies that can enhance immune cell infiltration and activation are critical to improving the outcome of cancer immunotherapy.
Disclosure of Invention
In order to solve the above problems, the present invention provides an alkaline phosphatase-responsive and convertible supermolecule bispecific cell cement polypeptide, a method for preparing the same and application thereof, and the present invention provides a novel method for solving challenges related to infiltration and activation of immune cells in cancer immunotherapy, introducing an alkaline phosphatase (ALP) -responsive and convertible supermolecule bispecific cell cement (Supra-BiCE) which utilizes the potential of NK and T cells for effective cancer immunotherapy.
In order to achieve the above object, the present invention provides the following technical solutions:
The invention provides an alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide, which is prepared by co-assembling a short peptide 1 and a short peptide 2;
The short peptide 1 is as follows: 1-Ada-GFFpY-GGYFHWHRLNP;
The short peptide 2 is as follows: 1-Ada-GFFpY-NYSKPTDRQYHF;
the 1-Ada is 1-adamantaneacetic acid;
The configuration of the amino acid in the short peptide 1 and the short peptide 2 is D configuration.
Preferably, both the short peptide 1 and the short peptide 2 are synthesized by Fmoc-solid phase synthesis.
Preferably, the Fmoc-solid phase synthesis method comprises the following steps:
(1) The C-terminus of Fmoc-amino acid was bound to the resin;
(2) Removing Fmoc protecting groups and washing;
(3) The C-terminal of the next Fmoc-amino acid is coupled with the N-terminal of the amino acid or polypeptide on the resin, and the resin is washed;
(4) Repeating the steps (2) - (3), and finally adding 1-adamantane acetic acid for washing;
(5) Cutting the polypeptide derivative from the resin to obtain a crude product;
(6) Purifying the crude product by high performance liquid chromatography to obtain short peptide 1 or short peptide 2.
The invention also provides a preparation method of the supermolecule bispecific cell cement polypeptide, which comprises the following steps:
1) Mixing the short peptide 1, the short peptide 2 and the phosphate buffer solution to obtain a short peptide solution, and regulating the pH value of the short peptide solution to 7.4 to obtain a solution to be assembled;
2) And (3) carrying out heating treatment and natural cooling on the solution to be assembled obtained in the step (1) to obtain the supermolecule bispecific cell cement polypeptide.
Preferably, the phosphate buffer in the step 1) is 1/2 x phosphate buffer, and the 1/2 x phosphate buffer contains 1% dimethyl sulfoxide by volume.
Preferably, the pH value of the short peptide solution is regulated by using a sodium carbonate solution, and the concentration of the sodium carbonate solution is 1mol/L.
Preferably, the ratio of the mass of the short peptide 1 and the mass of the short peptide 2 to the volume of the phosphate buffer solution in the step 1) is 1.157mg,1.192mg and 500 mu L.
Preferably, the heating treatment conditions in the step 2) include: the temperature was 90℃and the time was 10 minutes.
The invention also provides application of the supermolecule bispecific cell cement polypeptide in preparation of drugs for promoting NK and T cell immune infiltration of tumor cells.
Preferably, the tumor cells comprise the mouse breast cancer tumor cell line 4T1.
Supra-BiCE was constructed using a simple co-assembly strategy, combining two immune checkpoint blocking peptides: SA-P (short peptide 1), targeting and blocking programmed cell death ligand 1 (PD-L1) cells and SA-P (short peptide 2) on tumors, targets and blocks T cell immunoglobulins and ITIM domains (TIGIT) expressed by T cells and Natural Killer (NK) cells. This unique combination enables Supra-BiCE to selectively bind NK and T cells, promoting their activation and recruitment to enhance cancer immunotherapy.
Following administration via the tail vein, supra-BiCE self-assembles into nanoribbons and interacts with NK and T cells by binding to TIGIT. In tumor regions that overexpress ALP, the nanoribbon will be converted to long nanofibers in situ, resulting in an increased binding affinity of Supra-BiCE to PD-L1 and TIGIT. The transformation process is beneficial to the targeted enrichment and retention of NK cells and CD8+ T cells in a tumor area, and overcomes the limitation of poor infiltration of immune cells.
Advantageous properties and advantages: the Supra-BiCE design provides several significant characteristics and advantages in the field of cancer immunotherapy. First, it enables NK and T cells to bind locally to tumor cells, activating immune cells through dual immune checkpoint blockade. The method can remarkably improve the therapeutic effect of immunotherapy by overcoming limitations of immunocyte infiltration and immunosuppression tumor microenvironment.
Second, supra-BiCE demonstrates in situ enzyme-directed transformation behavior. The nanoribbons are converted into long nanofibers in the tumor area over-expressed by ALP, thereby increasing binding affinity to immune cells and tumor cells. This transformation process facilitates selective targeting, enrichment and retention of immune cells within the tumor, further enhancing the effectiveness of cancer immunotherapy.
Conclusion: in summary, alkaline phosphatase reactions and convertible Supra-BiCE represent a significant advance in the field of cancer immunotherapy. By addressing the limitations of immune cell infiltration and activation, this new approach makes it possible to significantly improve the therapeutic efficacy of solid tumor immunotherapy. The unique characteristics and advantages of Supra-BiCE, including its local binding to immune cells and tumor cells, in situ transformation, make it a promising tool for enhancing the effectiveness of cancer immunotherapy.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments will be briefly described below.
FIG. 1 is a structural formula and a high performance liquid chromatography mass spectrum of the polypeptide of example 2;
FIG. 2 is a structural formula and a high performance liquid chromatography mass spectrum of the polypeptide of example 3;
FIG. 3 is a structural formula and a high performance liquid chromatography mass spectrum of the polypeptide of comparative example 2;
FIG. 4 is a structural formula and a high performance liquid chromatography mass spectrum of the polypeptide of comparative example 3;
FIG. 5 is an optical view of solutions configured in examples and comparative examples;
FIG. 6 is a graph of the microscopic morphology of PBS solutions for example and control polypeptides;
FIG. 7 is a two-stage structure of the polypeptides of examples 1, 2, 3 and example 1 before and after ALP catalysis;
FIG. 8 is a copolymerization Jiao Tu of Cy 5-labeled example 1 polypeptide to promote NK cell and tumor cell adhesion;
FIG. 9 is a photograph showing in vivo imaging of the aggregation ability of the Cy5.5-labeled polypeptide at a tumor site in Experimental example 4;
FIG. 10 is a statistical graph of tumor volumes in experimental example 5;
FIG. 11 is a statistical graph of tumor suppression rate in experimental example 5;
FIG. 12 is a statistical graph of body weight monitoring during treatment of mice in Experimental example 5.
Detailed Description
The invention provides an alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide, which is prepared by co-assembling a short peptide 1 and a short peptide 2; the short peptide 1 is as follows: 1-Ada-GFFpY-GGYFHWHRLNP (SEQ ID No. 1); the short peptide 2 is as follows: 1-Ada-GFFpY-NYSKPTDRQYHF (SEQ ID No. 2); the 1-Ada is 1-adamantaneacetic acid; the configuration of the amino acid in the short peptide 1 and the short peptide 2 is D configuration.
In the present invention, the short peptide 1 and the short peptide 2 are preferably synthesized by adopting an Fmoc-solid phase synthesis method, the present invention is not particularly limited, and a person skilled in the art may adopt a conventional preparation method, and in a specific embodiment of the present invention, the Fmoc-solid phase synthesis method preferably includes the following steps:
(1) The C-terminus of Fmoc-amino acid was bound to the resin;
(2) Removing Fmoc protecting groups and washing;
(3) The C-terminal of the next Fmoc-amino acid is coupled with the N-terminal of the amino acid or polypeptide on the resin, and the resin is washed;
(4) Repeating the steps (2) - (3), and finally adding 1-adamantane acetic acid for washing;
(5) Cutting the polypeptide derivative from the resin to obtain a crude product;
(6) Purifying the crude product by high performance liquid chromatography to obtain short peptide 1 or short peptide 2.
The invention also provides a preparation method of the supermolecule bispecific cell cement polypeptide, which comprises the following steps:
1) Mixing the short peptide 1, the short peptide 2 and the phosphate buffer solution to obtain a short peptide solution, and regulating the pH value of the short peptide solution to 7.4 to obtain a solution to be assembled;
2) And (3) carrying out heating treatment and natural cooling on the solution to be assembled obtained in the step (1) to obtain the supermolecule bispecific cell cement polypeptide.
The preparation method comprises the steps of mixing the short peptide 1, the short peptide 2 and the phosphate buffer solution to obtain a short peptide solution, and adjusting the pH value of the short peptide solution to 7.4 to obtain a solution to be assembled. In the present invention, the phosphate buffer is preferably a 1/2 Xphosphate buffer, and the 1/2 Xphosphate buffer contains 1% by volume of dimethyl sulfoxide. The invention preferably uses sodium carbonate solution to adjust the pH value of the short peptide solution, and the concentration of the sodium carbonate solution is preferably 1mol/L. In the present invention, the ratio of the mass of the oligopeptide 1, the mass of the oligopeptide 2 and the volume of the phosphate buffer is preferably 1.157mg,1.192mg and 500. Mu.L.
The invention carries out heating treatment and natural cooling on the obtained solution to be assembled to obtain the supermolecule bispecific cell cement polypeptide. In the present invention, the conditions of the heat treatment preferably include: the temperature was 90℃and the time was 10 minutes.
The invention also provides application of the supermolecule bispecific cell cement polypeptide in preparation of drugs for promoting NK and T cell immune infiltration of tumor cells. In the present invention, the tumor cells preferably comprise the mouse breast cancer cell line 4T1.
In the examples of the present invention, the sources of the formulations involved are as follows:
2-Cl-Trt resin: available from Jier Biochemical (Shanghai) Inc. with a substitution of 1.158mmol/g.
Amino acid: purchased from gill biochemistry (Shanghai) limited with a purity of 98%.
N, N-Diisopropylethylamine (DIEPA): purchased from Shanghai Ala Biochemical technologies Co., ltd, purity was 99%.
2- (7-Azabenzotriazol) -N, N' -tetramethyluronium Hexafluorophosphate (HATU): the purity was 98% obtained from Tianjin Sheen Sichuang Biochemical technology Co.
Trifluoroacetic acid (TFA): commercially available from Shanghai Meilin Biochemical technologies Co., ltd.) at a purity of 99%.
Triisopropylsilane (TIS): purchased from Shanghai Ala Biochemical technologies Co., ltd, purity was 99%.
Anhydrous Dichloromethane (DCM): purchased from Tianjin chemical reagent company.
N, N-Dimethylformamide (DMF): purchased from Tianjin chemical reagent company.
Chromatographic pure methanol: commercially available from Tianjin Conscode technologies.
1-Adamantaneacetic acid: commercially available from Shanghai Ala Biochemical technologies Co.
Hoechst 33342 dye liquor: is commercially available from Shanghai Biyun biotechnology limited.
CFSE: is commercially available from Shanghai Biyun biotechnology limited.
Cy5: provided by the sameidie technology (Thermofisher Scientific).
Piperidine: purchased from Tianjin chemical reagent company.
Cell culture medium (DMEM): is provided by the Siemens technology (Thermofisher Scientific), and is sterile.
Fetal bovine serum: is provided by the Siemens technology (Thermofisher Scientific), and is sterile.
Balb/c mice: females at the age of 8 weeks were purchased from the company Vetolihua Biotechnology, inc.
The equipment involved in the embodiment of the invention is as follows:
High Performance Liquid Chromatograph (HPLC): manufactured by Lumtech in germany.
High performance liquid chromatography mass spectrometer: manufactured by shimadzu, model LC-MS2020.
An electronic balance: manufactured by Sarturious, germany, model BS124S.
Transmission Electron Microscope (TEM): tecnai G2F 20 System.
Freeze dryer: manufactured by Beijing Asia Taike Colon, model number is LGJ-1-50.
Laser confocal microscope: manufactured by Leica, germany, model number TCS SP8.
Round two chromatograph: manufactured by BioLogic, france, model number MOS-450.
The present invention will be described in detail with reference to examples for further illustration of the invention, but they should not be construed as limiting the scope of the invention.
Example 1
Synthesis of polypeptide 1-Ada-GFFpY-GGYFHWHRLNP (SA-T), polypeptide 1-Ada-GFFpY-NYSKPTDRQYHF (SA-P).
The polypeptide is SA-T or SA-P by adopting a classical Fmoc-short peptide solid phase synthesis method.
The method comprises the following specific steps:
In a solid phase synthesis tube, 0.5mmol of 2-Cl-Trt resin was taken, 15mL of DCM was added, and the mixture was placed on a shaker and shaken for 10 minutes to swell the 2-Cl-Trt resin.
DCM was extruded from a solid phase synthesizer loaded with 2-Cl-Trt resin using an ear-washing pellet.
0.75Mmol Fmoc protected amino acid was dissolved in 10mL DCM, 1.5mmol DIEPA was added, mixed well and added to a solid phase synthesizer and reacted at room temperature for 1 hour.
And (3) performing a sealing step: the reaction solution in the solid phase synthesis tube was removed, then washed with 10mL of DCM for 1 min each, 3 times, and then the prepared ratio of DCM was added: DIEPA: methanol was 17:1:2 in 16mL and reacted at room temperature for 15 minutes.
The reaction solution in the solid phase synthesis tube was removed, washed with DCM 10mL each for 1 min for 3 times, then DMF 10mL each for 1 min for 3 times. 15mL of DMF containing 20% piperidine was added and reacted for 30 minutes, followed by washing with DMF, 10mL each for 1 minute, and washing 5 times in total.
The second Fmoc protected amino acid 1mmol, HATU 1mmol, DIEPA2 mmol were weighed and dissolved in 10mL DMF, and the dissolved amino acid solution was added to the solid phase synthesis tube and reacted at room temperature for 1 hour.
The procedure of steps 5) and 6) was repeated with the amino acid and the blocking group 1-Ada being added sequentially. Then, the reaction mixture was washed with DMF for 5 times and dichloromethane for 5 times, and the reaction mixture was prepared for the next reaction.
10ML of the cleavage solution was prepared, and the mixture was added to a solid phase synthesizer in a ratio of 95% TFA,2.5% TIS and 2.5% H 2 O (volume ratio), and reacted at room temperature for 1 hour. The product was excised from the 2-Cl-Trt resin and the solvent removed by rotary evaporation to give the crude product. Subsequently, separation and purification are performed by HPLC to obtain SA-T or SA-P. As a result of LC-MS detection, as shown in FIGS. 1 and 2, the purity of SA-T and SA-P reaches 95% as can be seen from FIGS. 1 and 2.
Configuration of (SA-T & P):
1) Together, the lyophilized 1.157mg of SA-T and 1.192mg of SA-P were dissolved in 500. Mu.L of 1/2 XPBS buffer and 1% DMSO (volume ratio) was added to give a final concentration of SA-T & P solution of 500. Mu.M.
2) 1M Na 2CO3 was added to adjust the pH of the final solution to 7.4.
3) The solution was heated to 90 ℃ for 10 minutes and allowed to cool naturally to ensure adequate dissolution of the peptide.
4) In subsequent experiments, the prepared peptide-containing solution was diluted appropriately as needed to obtain the desired concentration, resulting in SA-T & P solution.
Example 2
Synthesis of polypeptide 1-Ada-GFFpY-GGYFHWHRLNP (SA-T).
The polypeptide is SA-T for short, which is synthesized by adopting a classical Fmoc-short peptide solid-phase synthesis method. The method comprises the following specific steps:
In a solid phase synthesis tube, 0.5mmol of 2-Cl-Trt resin was taken, 15mL of DCM was added, and the mixture was placed on a shaker and shaken for 10 minutes to swell the 2-Cl-Trt resin.
DCM was extruded from a solid phase synthesizer loaded with 2-Cl-Trt resin using an ear-washing pellet.
0.75Mmol Fmoc protected amino acid was dissolved in 10mL DCM, 1.5mmol DIEPA was added, mixed well and added to a solid phase synthesizer and reacted at room temperature for 1 hour.
And (3) performing a sealing step: the reaction solution in the solid phase synthesis tube was removed, then washed with 10mL of DCM for 1 min each, 3 times, and then the prepared ratio of DCM was added: DIEPA: methanol was 17:1:2 in 16mL and reacted at room temperature for 15 minutes.
The reaction solution in the solid phase synthesis tube was removed, washed with DCM 10mL each for 1 min for 3 times, then DMF 10mL each for 1 min for 3 times. 15mL of DMF containing 20% piperidine was added and reacted for 30 minutes, followed by washing with DMF, 10mL each for 1 minute, and washing 5 times in total.
The second Fmoc protected amino acid 1mmol, HATU 1mmol, DIEPA2 mmol were weighed and dissolved in 10mL DMF, and the dissolved amino acid solution was added to the solid phase synthesis tube and reacted at room temperature for 1 hour.
The procedure of steps 5) and 6) was repeated with the amino acid and the blocking group 1-Ada being added sequentially. Then, the reaction mixture was washed with DMF for 5 times and dichloromethane for 5 times, and the reaction mixture was prepared for the next reaction.
10ML of the cleavage solution was prepared, and the mixture was added to a solid phase synthesizer in a ratio of 95% TFA,2.5% TIS and 2.5% H 2 O (volume ratio), and reacted at room temperature for 1 hour. The product was excised from the 2-Cl-Trt resin and the solvent removed by rotary evaporation to give the crude product. Subsequently, separation and purification were performed by HPLC to obtain SA-T.
Configuration of SA-T solution:
1) The lyophilized 1.157mg SA-T was dissolved in 500. Mu.L of 1/2 XPBS buffer and 1% DMSO was added (volume ratio) to give a final concentration of SA-T solution of 500. Mu.M.
2) 1M Na 2CO3 was added to adjust the pH of the final solution to 7.4.
3) The solution was heated to 90 ℃ for 10 minutes and allowed to cool naturally to ensure adequate dissolution of the peptide.
4) In the subsequent experiments, the prepared peptide-containing solution was appropriately diluted as needed to obtain the desired concentration, resulting in SA-T solution.
Example 3
Synthesis of the polypeptide Ada-GFFpY-NYSKPTDRQYHF (SA-P).
The polypeptide is SA-P for short, which is synthesized by adopting a classical Fmoc-short peptide solid-phase synthesis method. The method comprises the following specific steps:
In a solid phase synthesis tube, 0.5mmol of 2-Cl-Trt resin was taken, 15mL of DCM was added, and the mixture was placed on a shaker and shaken for 10 minutes to swell the 2-Cl-Trt resin.
DCM was extruded from a solid phase synthesizer loaded with 2-Cl-Trt resin using an ear-washing pellet.
0.75Mmol Fmoc protected amino acid was dissolved in 10mL DCM, 1.5mmol DIEPA was added, mixed well and added to a solid phase synthesizer and reacted at room temperature for 1 hour.
And (3) performing a sealing step: the reaction solution in the solid phase synthesis tube was removed, then washed with 10mL of DCM for 1 min each, 3 times, and then the prepared ratio of DCM was added: DIEPA: methanol was 17:1:2 in 16mL and reacted at room temperature for 15 minutes.
The reaction solution in the solid phase synthesis tube was removed, washed with DCM 10mL each for 1 min for 3 times, then DMF 10mL each for 1 min for 3 times. 15mL of DMF containing 20% piperidine was added and reacted for 30 minutes, followed by washing with DMF, 10mL each for 1 minute, and washing 5 times in total.
The second Fmoc protected amino acid 1mmol, HATU 1mmol, DIEPA2 mmol were weighed and dissolved in 10mL DMF, and the dissolved amino acid solution was added to the solid phase synthesis tube and reacted at room temperature for 1 hour.
The procedure of steps 5) and 6) was repeated with the amino acid and the blocking group 1-Ada being added sequentially. Then, the reaction mixture was washed with DMF for 5 times and dichloromethane for 5 times, and the reaction mixture was prepared for the next reaction.
10ML of the cleavage solution was prepared, and the mixture was added to a solid phase synthesizer in a ratio of 95% TFA,2.5% TIS and 2.5% H 2 O (volume ratio), and reacted at room temperature for 1 hour. The product was excised from the 2-Cl-Trt resin and the solvent removed by rotary evaporation to give the crude product. Subsequently, separation and purification were performed by HPLC to obtain SA-P.
Configuration of SA-P solution:
1) 1.192mg of lyophilized SA-P was dissolved in 500. Mu.L of 1/2 XPBS buffer and 1% DMSO (volume ratio) was added to give a final concentration of SA-P solution of 500. Mu.M.
2) 1M Na 2CO3 was added to adjust the pH of the final solution to 7.4.
3) The solution was heated to 90 ℃ for 10 minutes and allowed to cool naturally to ensure adequate dissolution of the peptide.
4) In the subsequent experiments, the prepared peptide-containing solution was appropriately diluted as needed to obtain the desired concentration, resulting in a SA-P solution.
Comparative example 1
The Fmoc-short peptide solid phase synthesis method of example 1 was followed to prepare a polypeptide, abbreviated as T (GGYFHWHRLNP) or P (NYSKPTDRQYHF). In the synthesis of the control polypeptides, the gel forming factor consisting of 3 amino acids, 1-adamantane and alkaline phosphatase reaction sites were absent in the method of the comparative example. The polypeptide obtained in this comparative example is detected by high performance liquid chromatography mass spectrometry, the structural formula and the result of T are shown in figure 3, and the purity of T can reach 95% as can be seen from figure 3. The structural formula and the result of P are shown in FIG. 4, and the purity of P can be seen to reach 95% from FIG. 4.
Preparation of T & P solution:
1) 7.43mg of T and 7.78mg of P were dissolved together in 500. Mu.L of 1/2 XPBS buffer, and 1% DMSO (volume ratio) was added to give a final concentration of T & P solution of 500. Mu.M.
2) 1M Na 2CO3 was added to adjust the pH of the final solution to 7.4.
3) In subsequent experiments, the prepared peptide-containing solution was diluted appropriately as needed to obtain the desired concentration.
Comparative example 2
The Fmoc-short peptide solid phase synthesis method of example 1 was followed to prepare a polypeptide, abbreviated T (GGYFHWHRLNP). In the synthesis of the control polypeptides, the gel forming factor consisting of 3 amino acids, 1-adamantane and alkaline phosphatase reaction sites were absent in the method of the comparative example. The polypeptide obtained in this comparative example is detected by high performance liquid chromatography mass spectrometry, the structural formula and the result of T are shown in figure 3, and the purity of T can reach 95% as can be seen from figure 3.
Preparation of T solution:
1) 7.43mg of T was dissolved in 500. Mu.L of 1/2 XPBS buffer and 1% DMSO was added (volume ratio) to give a final concentration of 500. Mu.M.
2) 1M Na 2CO3 was added to adjust the pH of the final solution to 7.4.
3) In subsequent experiments, the prepared peptide-containing solution was diluted appropriately as needed to obtain the desired concentration.
Comparative example 3
The Fmoc-short peptide solid phase synthesis method of example 1 was followed to prepare a polypeptide, abbreviated P (NYSKPTDRQYHF). In the synthesis of the control polypeptides, the gel forming factor consisting of 3 amino acids, 1-adamantane and alkaline phosphatase reaction sites were absent in the method of the comparative example. The polypeptide obtained in this comparative example was detected by high performance liquid chromatography mass spectrometry, the structural formula and the result of P are shown in FIG. 4, and it can be seen from FIG. 4 that the purity of P reaches 95%.
Preparation of P solution:
1) 7.78mg of P was dissolved in 500. Mu.L of 1/2 XPBS buffer and 1% DMSO was added (volume ratio) to give a final concentration of 500. Mu.M in the P solution.
2) 1MNA 2CO3 was added to adjust the pH of the final solution to 7.4.
3) In subsequent experiments, the prepared peptide-containing solution was diluted appropriately as needed to obtain the desired concentration.
Experimental example 1
Transmission electron microscope experiment
The solutions of examples 1,2 and 3 were prepared and electron microscopy samples were prepared. First, 10. Mu.L of a 10. Mu.M polypeptide self-assembly solution was dropped onto a copper mesh, left for one minute, and then the excess solution was removed from the edges using filter paper. Next, 10 μl of phosphotungstic acid was added dropwise, left on the copper mesh for one minute for negative staining, and the excess dye solution was removed from the edge again using filter paper. And placing the treated copper net in a drying oven, and shooting by using an electron transmission microscope after the copper net is completely dried. ALP was then added to examples 1,2 and 3 at a rate of 10U/mL, and the mixture was placed in an incubator at 37℃and after 24 hours of reaction, the photograph of the solution was shown in FIG. 5, and the microstructure of examples 1,2 and 3 and the microstructure of example 1 converted by ALP catalysis were observed by a transmission electron microscope, and the result was shown in FIG. 6.
FIG. 6 shows that example 2 (SA-T) and example 3 (SA-P) form nanoparticles and short nanofibers, respectively. However, unlike example 2 (SA-T) and example 3 (SA-P), the co-assembled SA-T & P formed short nanoribbon structures, which demonstrated the occurrence of self-assembly. After the addition of ALP, example 1 undergoes a morphology transformation under the action of ALP, which is manifested as long nanofibers, which are then entangled to form a dense nanofiber network. The above results demonstrate that the addition of ALP does trigger the morphology transition of example 1.
Experimental example 2
Round two-chromatographic determination secondary structure
For CD signal detection, the sample (SA-T & P) was diluted to a concentration of 50. Mu.M according to the preparation method described in Experimental example 1. Then, 200. Mu.l of the diluted sample was put into a quartz cell having a diameter of 0.1 cm. CD spectra were recorded in the 190-260nm range using a circular dichroism spectrometer (MOS-450, bioLogic), as shown in FIG. 7.
SA-P shows two characteristic peaks, located at 210 and 221 nm, respectively, tending to form an alpha helix structure. SA-T shows a positive peak, employing a beta-sheet conformation at 223 nm. These results are consistent with FT IR. In addition, SA-T & P shows two positive peaks, located at 213 and 233 nm, respectively, indicating that the alpha helix structure is dominant. A strong positive value around 226 nm indicates that SA-T & P is dominant in the phosphatase-catalyzed beta sheet structure.
Experimental example 3
Laser confocal microscope study of attachment process of SA-BiCE and cells
Co-culture observations of NK and 4T1 cells: first, mouse NK cells were labeled with CFSE (Thermofisher C34554). Briefly, cells were co-incubated with CFSE for 10 minutes and then washed three times with PBS. Next, the experimental group was incubated with 10. Mu.M Cy 5-labeled example 1 for NK cells. Control groups were incubated with PBS. After 2 hours of incubation, the incubated NK cells were inoculated onto 4T1 cells (Hoechst-labeled) previously cultured to a density of about 80% together with Cy 5-labeled example 1, and the number ratio of NK cells to 4T1 cells was 4:1. then, an image was taken at the same voltage using a laser confocal microscope (LEICA TSC SP) as shown in fig. 8.
As can be seen from fig. 8, after the co-culture of cd8+ T and NK cells with example 1 for 12 hours, the non-adherent cells were washed out, and a large number of cd8+ T and NK cells were observed to be tightly bound to tumor cells and to be significantly adhered to the cell membranes of 4T1 cells. The control group had a lower number of CD8 + T and NK cells interacting with tumor cells than the control group.
Experimental example 4
Ability of SA-BiCE to aggregate at tumor sites
The ability of examples and controls to aggregate at tumor sites was evaluated using a small animal living imaging system. The polypeptide self-assembly solution of the example, as well as the solutions of the control and Cy5.5, were prepared according to the dosage calculation of the cyanine dye Cy5.5-NHS at a dosage of 2.09. Mu.M kg -1. The administration mode is tail vein injection, and the administration volume is 150 mu L. The mark was 0h (0 h) after the completion of the administration. Living imaging was performed at different time points (1 hour, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours) using an excitation wavelength of 645nm. The results are shown in FIG. 9.
All examples showed significantly enhanced fluorescence signal one hour after mouse tail intravenous injection compared to the control. This is probably because the assembled peptide has a greater resistance to biodegradation. Examples 2, 3 and 1 exhibited stronger tumor targeting and retention than comparative examples 2, 3 and 1. This is because the nanostructure formed by the assembly of the polypeptide can reach the tumor site through EPR effect in blood circulation and self-assemble according to ALP overexpressed around the tumor, thereby enhancing the retention ability at the tumor site. Interestingly, the retention capacity of example 1 in mice after 48 hours was significantly higher than for the groups of examples 2 and 3. This is believed to be due to the stronger binding capacity to PD-L1 of example 1, and the stronger aggregation capacity under ALP catalysis in the tumor microenvironment.
Experimental example 5
Animal tumor model
To evaluate the inhibitory effect of SA-BiCE on tumor growth, 4T1 cells were injected under mammary fat pad of 8-week-old BALB/c mice, each of which was injected with 2X 10 5 cells, and a 4T1 xenograft tumor model was established. The calculation formula for tumor volume was v=lw 2/2, where L and W represent the length and width of the tumor, respectively, and tumor size was monitored using vernier calipers. When the tumor volume reached 30-50mm 3, the mice were weighed and randomly divided into different groups. The experiments were performed by tail vein injection, and the mice were injected with the polypeptide derivative (6.5. Mu.M kg-1) and PBS every other day from day 6 for a total of 5 doses, and the tumor growth trend and the weight change of the mice in each group were monitored, as shown in FIG. 10. The experiment has obtained SYXK (jin) 2019-0003 certification No. issued by the ministry of the Tianjin city.
The results in FIG. 10 show that example 1 (SA-T & P) exhibited the best ability to resist tumor growth, reaching the highest level among all groups. The results according to fig. 11 show that the tumor suppression rate of example 1 was about 64.47% higher by 1.43-fold, 4.61-fold, 6.14-fold, 9.66-fold and 5.13-fold than that of example 2, example 3, comparative example 1, comparative example 2 and comparative example 3, respectively.
Fig. 12 is a statistical result of the monitoring of the body weight of mice during the treatment period, and the change of the body weight of the mice is found to be negligible, which indicates that none of the drugs shows obvious systemic toxicity, and the polypeptides provided by the invention have good biocompatibility.
The invention provides an innovative method, which utilizes the design of an ALP-responsive dual-specificity supermolecule cell engagement device (Supra-BiCE) to realize the targeted combination between cancer cells and immune cells so as to enhance the immune treatment effect. Through the co-assembly of blocking peptides, the Supra-BiCE can simultaneously recognize TIGIT on the surface of immune cells and PD-L1 on the surface of tumor cells, and through the conversion from ALP-guided nanofibers to long nanofibers, the binding affinity is improved, the recruitment of tumor-specific immune cells is ensured, and the retention in tumors is prolonged. This approach provides new strategies and tools for enhancing the effectiveness of immunotherapy.
Although the foregoing embodiments have been described in some, but not all, embodiments of the invention, it should be understood that other embodiments may be devised in accordance with the present embodiments without departing from the spirit and scope of the invention.
Claims (10)
1. An alkaline phosphatase responsive and transformable supramolecular bispecific cell cement polypeptide, characterized in that it is co-assembled from short peptide 1 and short peptide 2;
The short peptide 1 is as follows: 1-Ada-GFFpY-GGYFHWHRLNP;
The short peptide 2 is as follows: 1-Ada-GFFpY-NYSKPTDRQYHF;
the 1-Ada is 1-adamantaneacetic acid;
The configuration of the amino acid in the short peptide 1 and the short peptide 2 is D configuration.
2. The supramolecular bispecific cell cement polypeptide of claim 1, wherein both short peptide 1 and short peptide 2 are synthesized using Fmoc-solid phase synthesis.
3. The supramolecular bispecific cell cement polypeptide of claim 2, wherein the Fmoc-solid phase synthesis method comprises the steps of:
(1) The C-terminus of Fmoc-amino acid was bound to the resin;
(2) Removing Fmoc protecting groups and washing;
(3) The C-terminal of the next Fmoc-amino acid is coupled with the N-terminal of the amino acid or polypeptide on the resin, and the resin is washed;
(4) Repeating the steps (2) - (3), and finally adding 1-adamantane acetic acid for washing;
(5) Cutting the polypeptide derivative from the resin to obtain a crude product;
(6) Purifying the crude product by high performance liquid chromatography to obtain short peptide 1 or short peptide 2.
4. A method for preparing the supramolecular bispecific cell cement polypeptide of any one of claims 1-3, comprising the steps of:
1) Mixing the short peptide 1, the short peptide 2 and the phosphate buffer solution to obtain a short peptide solution, and regulating the pH value of the short peptide solution to 7.4 to obtain a solution to be assembled;
2) And (3) carrying out heating treatment and natural cooling on the solution to be assembled obtained in the step (1) to obtain the supermolecule bispecific cell cement polypeptide.
5. The method according to claim 4, wherein the phosphate buffer in step 1) is 1/2×phosphate buffer, and the 1/2×phosphate buffer contains 1% dimethyl sulfoxide by volume.
6. The method according to claim 4, wherein the pH of the short peptide solution is adjusted using a sodium carbonate solution having a concentration of 1mol/L.
7. The method according to claim 4, wherein the ratio of the mass of the short peptide 1 to the mass of the short peptide 2 to the volume of the phosphate buffer solution in the step 1) is 1.157 mg/1.192 mg/500. Mu.L.
8. The method according to claim 4, wherein the conditions of the heat treatment in step 2) include: the temperature was 90℃and the time was 10 minutes.
9. The use of the supramolecular bispecific cell cement polypeptide of any one of claims 1-3 in the preparation of a medicament for promoting NK and T cell immune infiltration of tumor cells.
10. The use according to claim 9, wherein the tumour cell is a mouse breast cancer cell line 4T1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311038473.6A CN117024517B (en) | 2023-08-17 | 2023-08-17 | Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311038473.6A CN117024517B (en) | 2023-08-17 | 2023-08-17 | Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117024517A CN117024517A (en) | 2023-11-10 |
CN117024517B true CN117024517B (en) | 2024-06-25 |
Family
ID=88624215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311038473.6A Active CN117024517B (en) | 2023-08-17 | 2023-08-17 | Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117024517B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853515A (en) * | 2018-06-28 | 2018-11-23 | 南开大学 | Preparation method and application, the pharmaceutical composition of small peptide hydrogel |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113024638B (en) * | 2021-03-12 | 2022-05-03 | 潍坊医学院 | Small molecular peptide and preparation method and application thereof as nano drug-loaded carrier |
CN114053437A (en) * | 2021-11-15 | 2022-02-18 | 南京大学 | Alkaline phosphatase response bimodal probe P-CyFF-68Ga and preparation method and application thereof |
CN115192730A (en) * | 2022-07-13 | 2022-10-18 | 郑州大学 | Bispecific polypeptide nano-drug targeting PD-L1 and preparation method and application thereof |
CN115340593B (en) * | 2022-10-17 | 2022-12-23 | 潍坊医学院 | Alkaline phosphatase responsive small molecule peptide, nano drug-loaded carrier and application |
-
2023
- 2023-08-17 CN CN202311038473.6A patent/CN117024517B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853515A (en) * | 2018-06-28 | 2018-11-23 | 南开大学 | Preparation method and application, the pharmaceutical composition of small peptide hydrogel |
Non-Patent Citations (1)
Title |
---|
短肽自组装水凝胶的温和制备方法及免疫佐剂应用;王友志等;《高分子学报》;20180131(第1期);9-20 * |
Also Published As
Publication number | Publication date |
---|---|
CN117024517A (en) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI788724B (en) | Cyclic peptide compound with Kras inhibitory effect | |
US4490291A (en) | Nonapeptide amides | |
JP7179241B1 (en) | Pharmaceutical Uses of Cyclic Peptide Compounds | |
JPH03504013A (en) | Peptide with T cell helper activity | |
JPS60120900A (en) | Lhph homologue nonapeptide and decapeptide useful as lhrh agonist | |
CN107522772B (en) | Short peptide, application of short peptide as vaccine adjuvant and vaccine using short peptide as vaccine adjuvant | |
DE60028544T2 (en) | PROSTATE SPECIFIC GENES FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF PROSTATE CANCER | |
CN110790829B (en) | Application of antibody prepared by using pHLIP extracellular segment as antigen in preparation of antitumor drugs | |
CN110746490B (en) | Polypeptide composition for blocking immune check point based on click reaction and preparation method and application thereof | |
CN106810610A (en) | Anti-EpCAM and the double targeting antibodies of CD3 specificity and its preparation method and application, the minicircle dna containing this pair of targeting antibodies expression cassette and application | |
CN117024517B (en) | Alkaline phosphatase response and convertible supermolecule bispecific cell cement polypeptide and preparation method and application thereof | |
Wang et al. | Supramolecular Hydrogels of Indole‐Capped Short Peptides as Vaccine Adjuvants | |
US20170158735A1 (en) | Method for producing a recombinant peptide and resultant peptide | |
CN111548419B (en) | DDR2 targeting polypeptide and application thereof | |
CN108864253B (en) | Linear pseudopolypeptide, preparation method thereof and application thereof in antitumor drugs | |
JP6552960B2 (en) | Methods for producing recombinant peptides and resulting peptides | |
CN117567638A (en) | Supermolecule polypeptide and application thereof, supermolecule cell cement and assembling method and application thereof | |
CN116281953A (en) | Base functionalized tumor targeting carbon dot and preparation method and application thereof | |
CN112028982A (en) | PD-L1-targeted covalent polypeptide inhibitor and preparation method and application thereof | |
CN109331177A (en) | A kind of immunity enhancement type polyvaccine and its preparation method and application | |
CN114805356A (en) | Linker arm for controlling activation/inhibition of chimeric antigen receptor T cells and application thereof | |
JPS6327360B2 (en) | ||
JPH0137399B2 (en) | ||
CN113072622B (en) | Polypeptide for selectively degrading PD-L1 protein on tumor cell membrane and application | |
JPS6149320B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |